Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Modulation of Morbidity and Disease Progression in Polycythemia Vera (PV) and Essential Thrombocythemia (ET) Patients With Obstructive Sleep Apnea (OSA) by CPAP

NCT03972943 is registered in ClinicalTrials.gov with University of Utah as lead sponsor.

NCT NCT03972943
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03972943 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Modulation of Morbidity and Disease Progression in Polycythemia Vera (PV) and Essential Thrombocythemia (ET) Patients With Obstructive Sleep Apnea (OSA) by CPAP
Lead sponsor
University of Utah
Phase
Phase 1
Overall status
Terminated
Start date
May 15, 2019
Completion date
July 28, 2023
Enrollment
8 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

calr gene mutation, essential thrombocythemia, jak2 gene mutation, mpl gene mutation, obstructive sleep apnea syndrome, polycythemia vera